Table 1.
Infectivity of HIV WT and HIV-YRRHHY > A5 virus-containing supernatants from samples with peak RT activities.
| Virus | Round of Infectiona | Relative Infectivityb (%) ± S.D.c |
Fold Decrease in Infectivity |
| WT | 1 | 100 ± 4.5 | - |
| YA | 1 | 11.6 ± 0.2 | 8.6 |
| YB | 1 | 13.6 ± 0.1 | 7.4 |
| YC | 1 | 14.2 ± 0.1 | 7.0 |
| WT | 2 | 100 ± 3.0 | - |
| YA | 2 | 10.6 ± 0.5 | 9.5 |
| YB | 2 | 7.3 ± 0.5 | 13.7 |
| YC | 2 | 4.6 ± 0.7 | 21.7 |
| WT | 3 | 100 ± 4.2 | - |
| YA | 3 | 0.9 ± 0.0 | 106.4 |
| YB | 3 | 5.2 ± 1.0 | 19.1 |
| YC | 3 | 2.2 ± 0.4 | 44.7 |
a Peak time points analyzed are shown in Fig. 2.
b The infectivity of equivalent volumes of cell supernatants was assessed using TZM-bl cells. Luciferase activities in infected cell lysates were measured 24 hours after infection.
c S.D., standard deviation.